[The vaccinal prophylaxis of hepatitis B among children born to mothers with persistent HBs-antigenemia].
In Uzbekistan and Moldova 542 children born of HBsAg carriers were immunized against hepatitis B (with vaccine Engerix B according to the immunization schedule of 4 injections). Anti-HBs antibodies in protective titers were detected by EIA and RIA techniques in 76.7% of children aged 4-5 months after the 3rd injection, in 95.7% of children aged 15-16 months and in 90.0% of children aged 2-2.5 years after the 4th (booster) injection. In the control group (117 nonimmunized children born of HBs carriers) observed during the same period anti-HBs antibodies were detected significantly less frequently (in 7.3%, 11.6% and 12.9% of these children respectively). 1-2 months after the course of immunization was completed 74.1% of the immunized children had high anti-HBs antibody titers (exceeding 1000 IU/ml) with their subsequent decrease by 2-2.5 years of age. In the control group these figures were 27.1% and 29.0% respectively. The index of immunization effectiveness obtained by the comparison of the hepatitis B morbidity rates in both groups was 7.8. No postvaccinal complications were registered.
Khukhlovich
P A
PA
Shakhgil'dian
I V
IV
Narkevich
M I
MI
Anan'ev
V A
VA
Kuzin
S N
SN
Sergeeva
N A
NA
Khodzhaev
Sh Kh
ShKh
Iarovoĭ
P I
PI
Drobeniuk
Zh A
ZhA
Iuldashev
A K
AK
Khodzhaeva
M A
MA
Makmudova
O N
ON
Buriev
A Ia
AIa
Rakhimov
R A
RA
Tuliaganova
G M
GM
Khasanova
V A
VA
Tsvaĭner
M I
MI
Eliseeva
T S
TS
Tuĭchibaeva
M A
MA
Mineecheva
L V
LV
Kotsaga
E I
EI
Nagachevskaia
V I
VI
Rafikova
N Kh
NKh
Klimenko
S M
SM
D000704:Analysis of Variance; D002353:Carrier State / Q000276:immunology*; D004341:Drug Evaluation; D005260:Female; D006509:Hepatitis B / Q000276:immunology* / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D017325:Hepatitis B Vaccines / Q000009:adverse effects / Q000276:immunology*; D006513:Hepatitis B e Antigens / Q000097:blood; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008966:Moldova; D011247:Pregnancy; D014610:Uzbekistan; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000276:immunology*
C075654:Engerix-B; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D006513:Hepatitis B e Antigens; D014614:Vaccines, Synthetic
Vaktsinoprofilaktika gepatita B sredi deteĭ, rodivshikhsia ot matereĭ s persistiruiushcheĭ HBs-antigenemieĭ.